RecruitingPhase 1Phase 2NCT05533697

Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

Phase 1/2 Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

Sponsor

ModernaTX, Inc.

Enrollment

361 participants

Start Date

Sep 1, 2022

Study Type

INTERVENTIONAL

Conditions

Advanced Solid Tumors

Summary

The primary goal of this study is to assess the safety and tolerability of mRNA-4359 administered alone and in combination with pembrolizumab or ipilimumab and nivolumab.

Eligibility

Min Age: 12 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called Ipilimumab, a biological treatment called Nivolumab, and others for people with advanced solid tumors. The study is currently recruiting participants at 34 locations. People eligible for this study include aged 12 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALmRNA-4359

Intramuscular Injection

BIOLOGICALPembrolizumab

Intravenous infusion

BIOLOGICALIpilimumab

Intravenous infusion

BIOLOGICALNivolumab

Intravenous infusion

Locations(39)

The Angeles Clinic and Research Institute

Los Angeles, California, United States

UCSF Helen Diller Family Comprehensive Cancer Center

San Francisco, California, United States

University of Colorado Cancer Center

Aurora, Colorado, United States

George Washington University

Washington D.C., District of Columbia, United States

Orlando Health UF Health Cancer Center

Orlando, Florida, United States

The University of Chicago Medicine

Chicago, Illinois, United States

Massachusetts General Hospital

Boston, Massachusetts, United States

Dana Farber Cancer Institute

Boston, Massachusetts, United States

Henry Ford Hospital

Detroit, Michigan, United States

Washington University

St Louis, Missouri, United States

John Theurer Cancer Center

Hackensack, New Jersey, United States

NYU Langone Health-Perlmutter Cancer Center

New York, New York, United States

Memorial Sloan Kettering Cancer Center - Melanoma & Immunotherapeutics

New York, New York, United States

Carolina BioOncology Institute

Huntersville, North Carolina, United States

Oregon Health & Science University

Portland, Oregon, United States

Sara Cannon Research Institute Tennessee

Nashville, Tennessee, United States

Southside Cancer Center

Miranda, New South Wales, Australia

Wollongong Hospital

Wollongong, New South Wales, Australia

Melanoma Institute Australia

Wollstonecraft, New South Wales, Australia

Austin Hospital

Melbourne, Victoria, Australia

One Clinical Research

Nedlands, Western Australia, Australia

Lungenfachklinik Immenhausen - Thoracic Oncology

Immenhausen, Hesse, Germany

A.O. Santa Maria della Misericordia

Udine, Perugia, Italy

Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie

Warsaw, Masovia, Poland

South Texas Accelerated Research Therapeutics (START) - Rioja

Logroño, La Rioja, Spain

NEXT Oncology Barcelona

Barcelona, Spain

Hospital Clinic De Barcelona - Oncología Médica

Barcelona, Spain

Hospital Universitario 12 de Octubre

Madrid, Spain

NEXT Oncology Madrid

Madrid, Spain

Hospital Regional Universitario de Málaga Parent Org

Málaga, Spain

Lancashire Teaching Hospitals NHS Foundation Trust - Royal Preston Hospital

Preston, Lancashire, United Kingdom

Beatson West of Scotland Cancer Centre

Glasgow, Scotland, United Kingdom

Queen Elizabeth Hospital Birmingham

Birmingham, United Kingdom

University College London Hospitals NHS Foundation Trust

London, United Kingdom

Guy's and St. Thomas' NHS Foundation Trust

London, United Kingdom

Imperial College London

London, United Kingdom

The Christie NHS Foundation Trust - Cancer Research Centre

Manchester, United Kingdom

Churchill Hospital

Oxford, United Kingdom

University Hospital Southampton NHS Foundation Trust

Southampton, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05533697

Related Trials

Study Evaluating ISM8207 in Participants With Advanced Solid Tumors and Relapsed/Refractory B-Cell Lymphoma

NCT064455174 locations

Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors

NCT042224132 locations

A Study to Evaluate Claudin 18.2-Directed ADC LCB02A in Advanced Solid Tumors

NCT074603758 locations

A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation

NCT0717291911 locations

A Study of ASP1002 in Adults for Treatment of Solid Tumors

NCT0571955815 locations